Please login to the form below
Wave Life Sciences
This page shows the latest Wave Life Sciences news and features for those working in and with pharma, biotech and healthcare.
Wave’s challenge to Sarepta in Duchenne falls flat
Shares in the company down more than 50%. Wave Life Sciences has abandoned two drugs for Duchenne muscular dystrophy, including phase 2/3 candidate suvodirsen, in a move that takes the ... The demise of Wave’s programmes leaves Japan’s Nippon
Latest news
-
UniQure gets speedy US review for Huntington’s gene therapy
The biotech’s one-shot gene therapy approach is up against other huntingtin-lowering therapies, including antisense-based therapies from Roche/Ionis and Takeda/Wave Life Sciences that attempt to bind ... Takeda and Wave have phase 1b/2a trial on the go
-
Duchenne UK and pharma partner pilot data-sharing HTA approach
The pharma partners - Roche, Sarepta Therapeutics, Solid Biosciences, Summit and Wave Life Sciences - all have an interest in DMD as well as other rare and orphan diseases that can have difficulties ... With a wave of treatments in, or about to enter
-
Pfizer signs $900m-plus deal with WAVE for metabolic R&D
Pfizer has bolstered its metabolic disease R&D with a $911m collaboration with WAVE Life Sciences focusing on nucleic acid-based therapies. ... The deal gives WAVE scope to use GalNAc in certain projects that lie outside the limits of the collaboration.
-
Life sciences sector 'aggressively embracing' new technology
report. The IMS Institute for Healthcare Informatics also found life sciences companies are 'aggressively embracing' new technology-driven approaches. ... The study, Riding the Information Technology Wave in Life Sciences: Priorities, Pitfalls and Promise
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Why everyone in pharma is bending over backwards to be agile
Flexibility is the new key to success. By Philip Atkinson. There is currently a significant wave of transformation across the life sciences sector. ... This takes time, but in all areas of life we need to respond quickly to a stimulus – it hurts when
-
25 Women Leaders in UK Healthcare
1. MELANIE LEE. Research leader. Melanie Lee is one of the most respected leaders in UK life sciences, having excelled in roles across the spectrum, from her early work in academic ... 8. DR SAM ROBERTS. Innovation translator. The UK life sciences sector
-
Deal Watch May 2016
950+ contingent 50. WaVe Life Sciences/ Pfizer. Licence and collaboration. Nucleic acid therapies for metabolic disorders using stereopure platform; $40m upfront includes $30m equity, option to up to 5 programmes.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
CHASE
We are a leading provider of outsourced commercial, medical and recruitment services to UK pharmaceutical, biotech and healthcare companies....
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
